COD GALBEN: 26-10-2021 Intre 00:20 si 06:00 se va semnala intensificări locale ale vântului care vor depăși temporar 55 - 60 km/h in Județul Caraş-Severin;

CURS BNR

EUR
4.9472Up
USD
4.2560Up
GBP
5.8502Down
CHF
4.6294Down
MDL
0.2433Down
BGN
2.5294Up
Sursa: Banca Naţională a României
View more
View less

Folow us

Modifică dimensiunea fontului:

 The National Coordinating Committee for Activities on Vaccination against COVID-19 (CNCAV) reported on Thursday that, according to assessments, the thrombosis syndrome associated with thrombocytopenia (TTS) is an extremely rare adverse reaction after vaccination with the second dose of the AstraZeneca vaccine and the recommendation is to carry out the booster with the same type of vaccine, except in cases of contraindication.

"Following reports of an extremely rare adverse reaction - thrombocytopenia-associated thrombosis syndrome (TTS) - after vaccination with Vaxzevria (AstraZeneca), the manufacturing company has continued to collect and analyse data from pharmacovigilance systems as required by regulatory bodies. In the database of the company AstraZeneca (global safety database) there were reported globally, until 30.04.2021, 13 cases of thrombosis syndrome associated with thrombocytopenia, occurred up to 14 days after the administration of the second dose, in people with the age between 45 - 85 years," a CNCAV release reads.

According to the source, symptoms often include shortness of breath, chest pain, swelling of the legs, severe and persistent abdominal pain, persistent headache, blurred vision, small bloodstains under the skin, away from the vaccine site.

The effectiveness of the vaccine is confirmed in the prevention of symptomatic and severe infections caused by both Alpha (B.1.1.7) and Delta (B.1.617.2) strains, according to calculations made by the UK Public Health Service.

CNCAV also mentions that "thrombosis syndrome associated with thrombocytopenia is a very rare side effect, and the benefits of COVID-19 vaccination outweigh the risks of side effects." AGERPRES (RO - author: Alina Novaceanu, editor: Claudia Stanescu; EN - editor: Adina Panaitescu)

The content of the www.agerpres.ro website has the exclusive purpose of public informing.
All the information published on this website by AGERPRES is protected by relevant legal dispositions.
It is forbidden to copy, reproduce, recompile, decompile, distribute, publish, display, modify, create derived components or products or full services, as well as any exploitation of the site's content.
Details in the section Terms of Use. If you are interested in picking up AGERPRES news items, please contact the Marketing Department – marketing@agerpres.ro.

The use of the Comments section entails your obligation to respect the AGERPRES terms and conditions in regards to the publishing of comments on the www.agerpres.ro.

Sursa: Administrația Națională de Meteorologie
Monitoring
Settings

ABOUT YOU

Dacă ai cont gratuit te loghezi cu adresa de email. Pentru a crea un cont gratuit accesează secțiunea “Crează cont”.

Dacă ai cont plătit te loghezi cu username. Pentru a vă crea un cont plătit vă rugăm să contactați:

Dacă nu puteți vizualiza această știre, contactați echipa AGERPRES pentru a vă abona la fluxurile de știri.